SCHEMBL30748843

SCHEMBL30748843

Clc1ncc2c(n1)N(c1cccc(Oc3ccccc3)c1)CC21CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 1/20 0.43
MAPT P10636 1/20 0.38
PIN1 Q13526 3/20 0.36
SLC6A2 P23975 1/20 0.35
SLC6A4 P31645 1/20 0.35
SLC6A3 Q01959 1/20 0.35
FNTA P49354 1/20 0.33
FNTB P49356 1/20 0.33
PGGT1B P53609 1/20 0.33
MAOB P27338 1/20 0.33
GRM5 P41594 1/20 0.32
CTSG P08311 1/20 0.32
CMA1 P23946 1/20 0.32
FFAR1 O14842 1/20 0.32
FFAR4 Q5NUL3 1/20 0.32
ABL1 P00519 1/20 0.31
MGLL Q99685 1/20 0.31
PIK3CD O00329 1/20 0.31
PIK3CA P42336 1/20 0.31
PIK3CB P42338 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30749030 0.91 PIN1 (0.40) PDE4BMAPTPIN1CTSGCMA1
SCHEMBL30749104 0.84 PDE4B (0.43) PDE4BSLC6A2SLC6A4SLC6A3FNTA
SCHEMBL30749095 0.82 PIN1 (0.36) PDE4BMAPTPIN1SLC6A2SLC6A4
SCHEMBL30749019 0.80 PDE4B (0.40) PDE4BMAPTGRM5PIK3CD
SCHEMBL30748882 0.77 PDE4B (0.39) PDE4BSLC6A2SLC6A4SLC6A3MGLL
SCHEMBL30749020 0.77 PIN1 (0.40) MAPTPIN1CTSGCMA1MGLL
SCHEMBL31691440 0.70 PTPN11 (0.34) PDE4BGRM5PIK3CA
SCHEMBL30749013 0.69 ALDH1A1 (0.44) MAPTPIK3CACYP1A2CYP2C9
SCHEMBL30748809 0.68 CCNE1 (0.45) MAPTPIN1MGLL
SCHEMBL30919710 0.62 BTK (0.47) MAPTPIN1MAOBCYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2025-10-02 US disclosed
EP-4565588-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF Suzhou Keen Therapeutics Co., Ltd. (CN) 2025-06-11 EP disclosed
WO-2023241620-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2023-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF VHL, BRCA1, TERT PDE4B 2287/4885MAPT 3029/4885PIN1 944/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.